Kairos Pharma to Showcase Innovative Cancer Therapeutics at H.C. Wainwright Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, is preparing to make a significant impact at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8 to 10, 2025. The company's participation includes hosting one-on-one meetings and delivering a presentation, which will also be accessible virtually. This event serves as a pivotal platform for Kairos Pharma to highlight its innovative strategies aimed at tackling drug resistance and immune suppression in cancer, two of the most formidable challenges in current oncology treatments.

Central to Kairos Pharma's research efforts is ENV105, an antibody designed to target CD105, a protein known to contribute to resistance against various cancer therapies. By focusing on CD105, ENV105 has the potential to reverse drug resistance, thereby improving the effectiveness of standard treatments across a range of cancer types. ENV105 is currently in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer, targeting conditions with high unmet medical needs. The company's involvement in the H.C. Wainwright conference is a testament to the promising impact its research could have on the future of cancer treatment.

For those interested in learning more about Kairos Pharma's presentation and its role in the conference, additional details are available here. Further information on Kairos Pharma and its pioneering work in the field of oncology can be found by visiting their official website.